We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

80 hedge funds and large institutions have $113M invested in Lineage Cell Therapeutics in 2015 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

508% more call options, than puts

Call options by funds: $3.08M | Put options by funds: $507K

240% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 5

42% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 19

16% more funds holding

Funds holding: 69 → 80 (+11)

0.72% more ownership

Funds ownership: 45.54% → 46.25% (+0.72%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

26% less capital invested

Capital invested by funds: $152M → $113M (-$38.9M)

Holders
80
Holders Change
+11
Holders Change %
+15.94%
% of All Funds
2.16%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
17
Increased
27
Reduced
19
Closed
5
Calls
$3.08M
Puts
$507K
Net Calls
+$2.58M
Net Calls Change
+$478K

Top Buyers

1
DWM
Destination Wealth Management
California
+$2.85M
2
TC
TFS Capital
Pennsylvania
+$1.24M
3
Renaissance Technologies
Renaissance Technologies
New York
+$793K
4
OAM
Oxford Asset Management
United Kingdom
+$544K
5
VKH
Virtu KCG Holdings
New York
+$385K

Top Sellers

1
CCM
Consonance Capital Management
New York
-$4.55M
2
CC
CQS Cayman
Cayman Islands
-$683K
3
MHP
Manatuck Hill Partners
Connecticut
-$623K
4
Citadel Advisors
Citadel Advisors
Florida
-$363K
5
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
-$223K
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
1
Broadwood Capital
New York
$64.7M – – –
BIT
2
BlackRock Institutional Trust
California
$6.91M -$33.2K -8,555 -0.4%
Vanguard Group
3
Vanguard Group
Pennsylvania
$5.53M +$341K +87,930 +5%
BFA
4
BlackRock Fund Advisors
California
$5.11M -$189K -48,685 -3%
AG
5
Artal Group
Luxembourg
$4.65M – – –
MHP
6
Manatuck Hill Partners
Connecticut
$4.18M -$623K -160,700 -10%
State Street
7
State Street
Massachusetts
$2.51M +$204K +52,523 +7%
CCM
8
Consonance Capital Management
New York
$2.38M -$4.55M -1,173,357 -59%
DWM
9
Destination Wealth Management
California
$2.15M +$2.85M +734,914 New
Northern Trust
10
Northern Trust
Illinois
$1.91M -$13.5K -3,479 -0.5%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$1.05M +$9.32K +2,404 +0.7%
TC
12
TFS Capital
Pennsylvania
$1M +$1.24M +320,719 +1,561%
Bank of New York Mellon
13
Bank of New York Mellon
New York
$871K +$176K +45,396 +18%
BIM
14
BlackRock Investment Management
Delaware
$683K +$172K +44,420 +24%
TCIM
15
TIAA CREF Investment Management
New York
$655K +$54.1K +13,963 +7%
Renaissance Technologies
16
Renaissance Technologies
New York
$599K +$793K +204,437 New
OAM
17
Oxford Asset Management
United Kingdom
$411K +$544K +140,390 New
FM
18
Family Management
New York
$397K +$213K +55,012 +68%
California State Teachers Retirement System (CalSTRS)
19
California State Teachers Retirement System (CalSTRS)
California
$345K +$2.06K +530 +0.5%
VKH
20
Virtu KCG Holdings
New York
$338K +$385K +99,324 +622%
GPCM
21
Granite Point Capital Management
Massachusetts
$321K -$128K -32,982 -23%
Morgan Stanley
22
Morgan Stanley
New York
$313K +$235K +60,570 +131%
Deutsche Bank
23
Deutsche Bank
Germany
$307K +$304K +78,431 +295%
Charles Schwab
24
Charles Schwab
California
$304K – – –
V
25
Veritable
Delaware
$291K -$12K -3,097 -3%
1
2 3 4

LCTX Hedge Fund Activity: Q2 2015 in Review

80 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2015, worth a combined $113M — down 26% from $152M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new LCTX positions and 5 closed out — a net gain of 12 holders — while 27 added to existing stakes and 19 trimmed.

The largest buyer was Destination Wealth Management, opening a new position worth an estimated $2.85M. The largest seller was Consonance Capital Management, cutting an estimated $4.55M.

  • 80 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2015, up from 69 in Q1 2015.
  • Funds reported $113M of Lineage Cell Therapeutics stock for Q2 2015, down 26% quarter-over-quarter.
  • 17 funds opened new Lineage Cell Therapeutics positions in Q2 2015 and 5 closed out, a net change of +12 holders.
  • The largest Lineage Cell Therapeutics buyer in Q2 2015 was Destination Wealth Management, an estimated $2.85M added.
  • The largest Lineage Cell Therapeutics seller in Q2 2015 was Consonance Capital Management, an estimated $4.55M sold.

Based on aggregated 13F filings for Q2 2015.